Abstract |
A pilot study was conducted to evaluate the effect of nizatidine on olanzapine-associated weight gain (OAWG) in ten patients with schizophrenia and schizophreniform disorder in Korea. Psychometric ratings with positive and negative syndrome scale (PANSS) and brief psychiatric rating scale (BPRS) were measured at baseline, week 4 and week 8; as were weight and body mass index (BMI). A combination of nizatidine for 8 weeks resulted in significant reversal of weight gain without worsening the psychopathology (weight: 3.5% and BMI: 3.7%). In line with studies of Western populations, an add-on therapy of nizatidine could be an effective option for the control of weight gain in olanzapine-treated patients in Korea. Our findings call for further evaluation of the effect of this drug on OAWG, with randomized placebo-controlled studies, in Asian populations.
|
Authors | Chi-Un Pae, Jung-Jin Kim, Kyung-Uk Lee, Chang-Uk Lee, Won-Myong Bahk, Soo-Jung Lee, Chul Lee, In-Ho Paik |
Journal | Human psychopharmacology
(Hum Psychopharmacol)
Vol. 18
Issue 6
Pg. 453-6
(Aug 2003)
ISSN: 0885-6222 [Print] England |
PMID | 12923823
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2003 John Wiley & Sons, Ltd. |
Chemical References |
- Antipsychotic Agents
- Histamine H2 Antagonists
- Benzodiazepines
- Pirenzepine
- Olanzapine
- Nizatidine
|
Topics |
- Adult
- Antipsychotic Agents
(adverse effects, therapeutic use)
- Benzodiazepines
- Female
- Histamine H2 Antagonists
(administration & dosage, therapeutic use)
- Humans
- Male
- Nizatidine
(administration & dosage, therapeutic use)
- Obesity
(etiology, prevention & control)
- Olanzapine
- Pilot Projects
- Pirenzepine
(adverse effects, analogs & derivatives, therapeutic use)
- Psychiatric Status Rating Scales
- Psychometrics
- Schizophrenia
(diagnosis, drug therapy)
- Weight Gain
(drug effects)
|